Owlet, Inc.

NYSE:OWLT

Medical - Devices

Healthcare
$3.67 +9.76%

+$0.46 today

Market cap
$107.24M
Beta
1.86
P/E (TTM)
-0.4
EPS (TTM)
-$12.67
52W Low $4.19High $16.94

Volume 0.64M

Average 0.24M

OWLT Debt Repayment

Cash used to repay borrowings during the period.

Owlet, Inc.NYSE: OWLT

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment growth accelerates

Q1 FY2026 debt repayment of $5.4M rose 179.5% year over year, ahead of the -30.5% change in trailing-twelve-month debt repayment.

Context

  • Debt repayment amounted to 0.1% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Debt repayment increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +179.5% holds above the trailing-twelve-month pace of -30.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.4M+144.0% QoQ
Last fiscal yearDec 2025
$55K+106.7% YoY
LTMMar 2026
$3.52M-30.5% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+179.5%——
1 year+106.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
55K USD
Year-over-year change
+106.7%

Debt Repayment vs competitors

How OWLT compares with its peers on the latest reported figures

  • OWLT's LTM Mar 2026 debt repayment of $3.52M is the 3rd largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -30.5% is the 3rd highest of 7, against a peer median of -54.7%.
  • Debt repayment amounts to 3.3% of revenue for OWLT, versus a peer median of 0.0%.
OWLT Competitors Peer median
Debt Repayment for OWLT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$19.09M +59756.3%—55.5%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$9.87M -50.0%——
OWLTOwlet, Inc.LTM Mar 2026$3.52M -30.5%—3.3%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.25M -59.5%+8.3%67.7%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
MXCTMaxCyte, Inc.LTM Mar 2026$0 ——0.0%
LUCDLucid Diagnostics Inc.LTM Mar 2026$0 -100.0%—0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 +100.0%——
LNSRLENSAR, Inc.LTM Mar 2026$0 -100.0%—0.0%
CRDFCardiff Oncology, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding OWLT) $0-54.7%+8.3%0.0%

Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.7M)(79.34M)(32.9M)(12.54M)(38.46M)
Depreciation & Amortization1.13M2.67M2.21M1.38M590K
Deferred Income Tax00000
Stock-Based Compensation4.26M12.86M9.93M8.63M9.35M
Change in Working Capital9.45M(15.2M)(4.82M)(2.52M)(10.71M)
Accounts Receivables(144K)(8.5M)965K2.03M(10.97M)
Inventory(11.65M)(1.18M)12.12M(4.14M)(4.93M)
Accounts Payables32.12M(10.72M)(19.5M)1.32M5.43M
Other Working Capital(10.87M)5.2M1.6M(1.74M)(236K)
Other Non-Cash Items16.3M(2.37M)2.05M(6.16M)28.43M
Operating Cash Flow(40.56M)(81.38M)(23.53M)(11.21M)(10.8M)
Capital Expenditures(2.02M)(1.57M)(59K)(761K)(273K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(1.05M)(929K)(43K)(726K)0
Investing Cash Flow(2.02M)(1.57M)(59K)(761K)(943K)
Debt Repayment(3.49M)(1.5M)156K(816K)55K
Common Stock Issued00010M34.69M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities124.11M618K269K(2M)(2.64M)
Financing Cash Flow120.62M(878K)28.91M16.04M32.1M
Effect of Forex Changes00000
Net Change in Cash78.05M(83.82M)5.33M4.07M20.38M
Free Cash Flow(42.58M)(82.95M)(23.59M)(11.97M)(11.07M)

Owlet, Inc.

NYSE:OWLT

Intrinsic Alpha fair value

Locked

Current Price

$3.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.